Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma

NCT07554898 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

MALT Lymphoma

Interventions

DRUG: Orelabrutinib
RADIATION: Ultra-low-dose Radiation Therapy

Sponsor

Zhejiang Cancer Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]